Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective, Multicenter, Observational Study to Evaluate Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in Japanese Patients With HR+/HER2- Advanced Breast Cancer in First Line or Second Line Settings

NCT05399329 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05399329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective, Multicenter, Observational Study to Evaluate Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in Japanese Patients With HR+/HER2- Advanced Breast Cancer in First Line or Second Line Settings
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
April 20, 2022
Completion date
June 27, 2025
Enrollment
693 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer